Zdrowie i gospodarka · 28/12/2020

FDA to Host Public Meeting on Interim Assessment of BsUFA Program

The Food and Drug Administration (FDA) is hosting a public meeting to discuss the interim assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA) and is seeking public comments on the program's progress. The meeting aims to gather public stakeholder views on the program's effectiveness to date.